Charles River Laboratories (CRL) said it will distribute several Pfizer-developed R&D models, in a deal that continues the US CRO’s efforts to expand its lab animals business.
Eli Lilly is transitioning discovery bioanalytical capabilities to Advion BioServices’ new laboratory, due to open in May, and staff may also transfer.
Contract research organisation (CRO) Maccine will set up a preclinical imaging laboratory in partnership with the Singapore Bioimaging Consortium (SBIC) under a deal announced late last week.
Lab Research's main Canadian lender has obtained an order appointing receivers under section 243 of the bankruptcy and insolvency act after the firm's US private equity suitor lost interest in a takeover.
Non-clinical CRO CIT will distribute Stemina’s hES-based toxicity testing platform to pharmaceutical and cosmetics developers in Europe under an agreement announced late last week.
US-based Numira Biosciences has expanded its imaging and pre-clinical services portfolio after acquiring the efficacy pharmacology operating unit of Ricerca Biosciences.
German biotech firm Evotec has expanded its drug discovery and early development platform with the acquisition of Munich-based chemical proteomics specialists, Kinaxo.
QPS Holdings has acquired Taiwan’s Center of Toxicology and Preclinical Sciences (CTPS), continuing its expansion in the region’s rapidly expanding drug development sector.
Establishment of complex regulated preclinical studies in China is going to take a lot longer than expected, says CRL, with significant progress taking at least five years.
Lab Research has signed a non-binding letter of intent (LOI) with a US private equity group interested in acquiring the preclinical contract research organisation (CRO).
Pfizer’s Centres for Therapeutic Innovation (CTI) has teamed up with seven New York research hospitals to accelerate biomedical research into life-saving medicines, with a focus on biologics.
Contract Research Organisation (CRO) Calvert Labs has launched a new iPhone “app” that lets customers track the progress of preclinical research projects with their mobile phones.
French contract research organisation (CRO) CIT will work on in vitro toxicity testing for pharmaceutical and cosmetic ingredients as the newest member of the European “ScreenTox” network.
Caliper Life sciences has entered into a definitive merger agreement with Cambridge Research & Instrumentation (CRi) to boost its discovery biomarker and personalised medicine development offering.
Caliper Life Sciences has begun toxicity testing on the final 350 compounds covered by the US Environmental protection Agency’s (EPA) ToxCast screening programme.
Advinus Therapeutics is to use Corning Epic label-free detection to provide clients in India and abroad with biologically relevant drug discovery data.
Animal welfare watchdog group, Stop Animal Exploitation Now (SAEN), has released documents which, it claims, provide evidence that CRO MPI Research has been operating in violation of the US Animal Welfare Act.
ShangPharma expects its cGMP production site, due to open in 2011, and biologics services to drive growth as it builds on a 17 per cent increase in revenues in the third quarter.
Demand for drug discovery, development services and active pharmaceutical ingredients (APIs) were the main growth drivers in Q3 according to Wuxi Pharmatech.
A Lack of animal models and difficulties in proving early clinical efficacy are hampering discovery and development of psychiatric drugs according to new consortium, NEWMEDS.
WuXi has received GLP certification from the SFDA for its toxicology facility in Suzhou, China and, in a separate development, is providing CAS’ SciFinder to its staff.
Inaccurate predictions based on animal models are the biggest cause of clinical failure according to Scottish CRO Biopta, which says use of human tissue samples for preclinical development would cut attrition rates.
Minipigs are a practical and flexible model for safety testing which probably provide better prediction of toxicity in humans than rats and dogs, according to EU funded research.
SAGE Labs has unveiled plans to create rodent autism models for preclinical drug discovery and development in collaboration with advocacy group Autism Speaks.
Predictive Biomarker Sciences (PBS-Bio) is collaborating with ENDECE, Revalesio and Unibioscreen to help bring new cancer drugs to the marketplace faster.
Horizon Discovery will use its X-MAN human disease cell line models to identify patients likely to benefit from Cylene Pharmaceuticals’ candidate cancer drug, CX-4945.
Beta-Pro is addressing rising demands from drug discovery and research institutes in the hepatocyte market by expanding its site at the University of Virginia Research Park, US, with a new GLP facility.
Covance has forged a new deal with InPhoton to provide clients with access to intravital microscopy imaging technology to address drug discovery and development questions across the preclinical space.
Charles River Laboratories (CRL) has added two new exclusive knockout rats to its preclinical development offering in deal with Transposagen Biopharmaceuticals.
Galapagos’ acquisition, Argenta, has signed up to a $46m cancer drug discovery service deal with Janssen Pharmaceutica, aimed at delivering novel cancer drug candidates.
Precos is aiming to accelerate growth of its attrition-reducing preclinical oncology screening services by naming a co-founder of ClinPhone as chairman.
Anglo-German company Evotec is joining forces with Almirall to identify small molecule modulators of an ion channel target involved in respiratory diseases.
Porsolt seeks to broaden its services and client base with a new US AAALAC accredited preclinical contract research facility providing non-GLP and GLP specialist pharmacology services to the global pharmaceutical and biotech industry.